An evaluation of patritumab deruxtecan for the treatment of EGFR-mutated non-small cell lung cancer
{{output}}
Introduction: Epidermal growth factor receptor (EGFR) mutations represent targetable alterations in non-small cell lung cancer (NSCLC). The treatment landscape in the frontline setting for patients with advanced EGFR-mutated NSCL... ...
